Comparative study between concomitant and tailored therapies for helicobacter pylori eradication

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006120

Enrollment

290

Registered

2021-05-06

Start date

2020-07-06

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : ? Concomitant therapy: rabeprazole 20 mg, amoxicillin 1.0 g, metronidazole 500 mg, clarithromycin 500 mg bid for 2 weeks po ? Tailored group: rabeprazole 20 mg, amoxicillin 1.0 g, clarithromyc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Persons who needs to receive Helicobacter pylori test ? No history of H. pylori treatment ? No history of antibiotics use within 1 month ? Persons who agree to the study process and goal

Exclusion criteria

Exclusion criteria: ? Recent antibiotics use within 1 month ? Person who received subtotal gastrectomy ? Person who has a severe hepatic, renal, and cardiopulmonary abnormality ? Person who do not agree to attend this study

Design outcomes

Primary

Measure	Time frame
Eradication success rate	—

Secondary

Measure	Time frame
Side effect rate	—

Countries

Korea, Republic of

Contacts

Public ContactSujin Kim

Pusan National University Yangsan Hospital

endoksj@gmail.com+82-55-360-1535

Outcome results